Inhibition of macrophage proinflammatory cytokine expression by steroids and recombinant IL-10

Biology of the Neonate

Volumn 80, Issue 2, 2001, Pages 124-132

  Li, Ying Hua ^a   Brauner, Annelie ^a   Jonsson, Baldvin ^a   Van Der Ploeg, Ingeborg ^a   Söder, Olle ^a   Holst, Mikael ^a   Jensen, Jørgen Skov ^b   Lagercrantz, Hugo ^a   Tullus, Kjell ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

Chronic lung disease; IL 6; Lipopolysaccharide; Recombinant IL 10; Steroids; TNF ; Ureaplasma urealyticum

Indexed keywords

ANTIINFLAMMATORY AGENT; BACTERIAL ANTIGEN; BUDESONIDE; DEXAMETHASONE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; RECOMBINANT INTERLEUKIN 10; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY FLUID; CELL LINE; CELL STIMULATION; CHRONIC LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; INFLAMMATORY CELL; LUNG ALVEOLUS MACROPHAGE; MALE; NEWBORN; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; REGULATORY MECHANISM; STEROID THERAPY; TRACHEOBRONCHIAL TREE;

ANIMALS; ANTIGENS; BUDESONIDE; CELL LINE; CYTOKINES; DEXAMETHASONE; FEMALE; GENE EXPRESSION; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTERLEUKIN-10; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MACROPHAGES, ALVEOLAR; MALE; RATS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA; UREAPLASMA UREALYTICUM;

UREAPLASMA UREALYTICUM;

EID: 0034880454     PISSN: 00063126     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047131     Document Type: Article

References (42)

1. Antioxidants, nutrition, and bronchopulmonary dysplasia
2. Clinical relevance of Ureaplasma urealyticum colonization in pre-term infants
3. Vaginal Ureaplasma urealyticum colonization: Influence on pregnancy outcome and neonatal morbidity
4. Ureaplasma urealyticum and pulmonary outcome in a neonatal intensive care population
5. Corticosteroids and neonatal chronic lung disease
6. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia
7. Long-term follow-up of severe respiratory distress syndrome treated with IPPB
8. Twelve years' experience with bronchopulmonary dysplasia
9. The evolution of neonatal respiratory distress syndrome into chronic lung disease
10. Bronchopulmonary dysplasia: Then and now
11. Early increase of TNF alpha and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants
12. Elevated cytokine levels in tracheobronchial aspirate fluids from ventilator treated neonates with bronchopulmonary dysplasia
13. Ureaplasma urealyticum and chronic lung disease in very low birth weight infants during the exogenous surfactant era
14. Association of Ureaplasma urealyticum in the placenta with perinatal morbidity and mortality
15. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia
16. Markers and mediators of inflammation in neonatal lung disease
17. IL-10 inhibits cytokine production by activated macrophages
18. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
19. 2 production by lipopolysaccharide-stimulated monocytes
20. Enhanced expression of interleukin (IL)-1 and IL-6 messenger RNA and bioactive protein after hypoxia-ischemia in neonatal rats
21. Ureaplasma urealyticum-induced production of proinflammatory cytokines by macrophages
22. Dexamethasone therapy in neonatal chronic lung disease: An international placebo-controlled trial
23. Randomized controlled trial of dexamethasone treatment in very-low-birth-weight infants with ventilator-dependent chronic lung disease
24. A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: A randomized trial
25. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants
26. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease
27. Sequential expression of genes involved in human T lymphocyte growth and differentiation
28. Regulation of c-myc mRNA levels in normal human lymphocytes by modulators of cell proliferation
29. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992
30. Comparison of the inhibition by glucocorticosteroids and cyclosporin A of mitogen-stimulated human lymphocyte proliferation
31. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells
32. Mode of action of corticosteroids in asthma and rhinitis
33. Glucocorticoid-receptor complexes in rat thymus cells. Rapid kinetic behavior and a cyclic model
34. Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process
35. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma
36. Dissociation of steroid binding to receptors and steroid induction of biological activity in a glucocorticoid-responsive cell
37. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10
38. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells
39. OKT3-induced cytokine mRNA expression in human peripheral blood mononuclear cells measured by polymerase chain reaction
40. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression
41. Rat tumor necrosis factor-alpha. Transcription in rat Kupffer cells and in vitro posttranslational processing based on a PCR-derived cDNA
42. Induced expression of mRNA for IL-5, IL-6, TNF-alpha, MIP-2 and IFN-gamma in immunologically activated rat peritoneal mast cells: Inhibition by dexamethasone and cyclosporin A